Eli Lilly and Company issued an 8-K press release on November 5, 2026, disclosing new Phase 3 clinical trial results for retatrutide and for the combination of Taltz and Zepbound, to be presented at the American College of Rheumatology Convergence 2026 conference beginning November 6 in Orlando.

Key Highlights

  • TRIUMPH-4 pain reduction: In the 68-week Phase 3 trial, retatrutide reduced knee osteoarthritis pain by up to an average of 4.5 points (75.8%) from an average baseline of 6.0 on the WOMAC pain subscale.
  • TRIUMPH-1 pain reduction: In the 80-week Phase 3 trial, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) from a baseline of 6.0 on the WOMAC pain subscale.
  • No knee pain outcomes: More than 1 out of 8 retatrutide-treated patients in TRIUMPH-4 and more than 1 out of 6 in TRIUMPH-1 experienced no knee pain at the end of their respective trials, according to the filing.
  • TOGETHER-PsA 52-week data: The proportion of patients achieving ACR50 with Taltz and Zepbound reached 43.7% at Week 52, compared with 15.7% for Taltz monotherapy, the filing stated.
  • Retatrutide status: The filing noted that retatrutide is investigational and "cannot be legally sold or marketed for human use."
  • Conference timing: Presentations are scheduled for November 8, 10, and 11, 2026, at ACR Convergence 2026 in Orlando.

Lilly Discloses Retatrutide and Immunometabolic Combination Data Ahead of ACR 2026

According to the filing, Eli Lilly and Company (NYSE:LLY) will present clinical and real-world research at ACR Convergence 2026 covering two investigational and approved treatment approaches for patients with rheumatologic conditions and obesity. The disclosures center on retatrutide, described in the filing as "an investigational once-weekly GIP, GLP-1, and glucagon triple hormone receptor agonist," and on the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with psoriatic arthritis and obesity or overweight.

For retatrutide, the filing detailed results from two Phase 3 trials. In TRIUMPH-4, a 68-week trial, retatrutide reduced knee osteoarthritis pain by up to an average of 4.5 points (75.8%) from an average baseline of 6.0 as measured by the WOMAC pain subscale. In TRIUMPH-1, an 80-week trial testing three doses, the reduction reached up to 4.3 points (73.1%) from a baseline of 6.0. The filing noted that more than 1 out of 8 patients in TRIUMPH-4 and more than 1 out of 6 in TRIUMPH-1 experienced no knee pain at trial end. The filing noted that approximately 80% of people with knee osteoarthritis have obesity or overweight, "which is associated with worse pain and functional outcomes."

For the TOGETHER-PsA study, the filing reported 52-week findings showing that the proportion of patients achieving ACR50 with Taltz and Zepbound increased from Week 36 to 43.7% at Week 52, versus 15.7% for Taltz monotherapy. The filing stated that an estimated 65% of people with psoriatic arthritis in the U.S. have obesity or overweight with at least one weight-related comorbidity. Adrienne Brown, identified in the filing as executive vice president and president of Lilly Immunology, was quoted describing the data as reflecting "Lilly's commitment to advancing immunometabolic health."

What Was Disclosed

Lilly disclosed Phase 3 clinical trial results for the investigational drug retatrutide in knee osteoarthritis and 52-week TOGETHER-PsA combination data for Taltz and Zepbound, all set for presentation at ACR Convergence 2026 in Orlando from November 6-11, 2026.